What to Expect When You Join This LIVE Webinar
International Myeloma Foundation (IMF) Vice President of Patient Support Robin Tuohy will moderate presentations and discussions with:
This educational webinar from the International Myeloma Foundation featured Dr. Beth Faiman (Cleveland Clinic) and Dr. Zainab Shahid (Memorial Sloan Kettering) discussing infection risks in multiple myeloma patients and prevention strategies. The presentation covered why myeloma patients face elevated infection risks, what types of infections to watch for, and comprehensive prevention approaches including vaccinations, prophylactic medications, and lifestyle measures.
Key Points
Why Myeloma Patients Are at Higher Risk:
- 5-7 times greater infection risk than general population
- Myeloma disrupts plasma cells that produce protective antibodies
- Highest risk during first months of treatment and later in disease progression (bimodal distribution)
- Treatment-induced low white blood cell counts increase vulnerability
Risk Factors Beyond Myeloma:
- Comorbidities: diabetes, kidney disease, heart disease
- Low immunoglobulin levels (hypogammaglobulinemia)
- Specific treatments (CAR T-cell therapy, bispecific antibodies carry highest risk)
- Older age and immune system aging
Prevention Strategies:
- Prophylactic medications: Acyclovir/valacyclovir (shingles prevention), Bactrim (PJP prophylaxis for CAR T/bispecific patients)
- Vaccinations: Seasonal flu, COVID-19, pneumococcal, RSV (age-appropriate), and shingles vaccines
- Post-CAR T revaccination: Starting at 6 months with multiple vaccines
- IVIG therapy: For patients with recurrent sinopulmonary infections and low IgG levels
- Basic precautions: Hand hygiene, masking in crowds/healthcare settings, avoiding sick contacts
Treatment-Specific Guidance:
- Traditional therapies (lenalidomide, bortezomib): Lower risk, mainly shingles prevention needed
- Anti-CD38 antibodies: Moderate risk, watch for pneumonia and viral infections
- CAR T/bispecific antibodies: Highest risk, requiring comprehensive prophylaxis and close monitoring for 90+ days
Key Message: Infection prevention should be individualized based on treatment phase, specific therapies, blood counts, and personal risk factors through ongoing discussion with healthcare providers.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Zainab Shahid, MD, MPH, FACP, FIDSA
Memorial Sloan Kettering Cancer Center
The Living Well with Myeloma Webinar will conclude with a summary discussion and a Live Q&A, offering attendees an opportunity to address specific concerns. Please join us for this informative session focused on Infection Prevention & Management.
We look forward to your active participation in this LIVE webinar. Be engaged and empowered!
With support from
